Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland.

Koskela-Niska V, Riska A, Lyytinen H, Pukkala E, Ylikorkala O.

Gynecol Oncol. 2012 Aug;126(2):241-4. doi: 10.1016/j.ygyno.2012.04.045. Epub 2012 May 2.

PMID:
22561401
2.

Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma.

Koskela-Niska V, Pukkala E, Lyytinen H, Ylikorkala O, Dyba T.

Int J Cancer. 2015 Oct 15;137(8):1947-52. doi: 10.1002/ijc.29549. Epub 2015 Apr 21.

PMID:
25846583
3.

Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.

Koskela-Niska V, Lyytinen H, Riska A, Pukkala E, Ylikorkala O.

Climacteric. 2013 Feb;16(1):48-53. doi: 10.3109/13697137.2012.663818. Epub 2012 May 28.

PMID:
22640598
4.

A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.

Korhonen K, Auvinen A, Lyytinen H, Ylikorkala O, Pukkala E.

Am J Epidemiol. 2012 Feb 15;175(4):309-14. doi: 10.1093/aje/kwr335. Epub 2012 Jan 27.

5.

Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.

Lyytinen H, Pukkala E, Ylikorkala O.

Obstet Gynecol. 2009 Jan;113(1):65-73. doi: 10.1097/AOG.0b013e31818e8cd6.

PMID:
19104361
6.

Endometrial cancer in postmenopausal women using estradiol-progestin therapy.

Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O.

Obstet Gynecol. 2009 Dec;114(6):1197-204. doi: 10.1097/AOG.0b013e3181bea950.

PMID:
19935019
7.

Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study.

Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E.

Int J Cancer. 2011 Apr 1;128(7):1644-51. doi: 10.1002/ijc.25762. Epub 2011 Jan 12.

8.

Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer.

Jaakkola S, Pukkala E, K Lyytinen H, Ylikorkala O.

Int J Cancer. 2012 Aug 15;131(4):E537-43. doi: 10.1002/ijc.27321. Epub 2011 Dec 14.

9.

Menopausal hormone therapy and risk of epithelial ovarian cancer.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56.

10.

Long-term postmenopausal hormone therapy and endometrial cancer.

Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):475-83. doi: 10.1158/1055-9965.EPI-09-0712. Epub 2010 Jan 19.

11.
12.

Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004.

Riska A, Sund R, Pukkala E, Gissler M, Leminen A.

Int J Cancer. 2007 Mar 15;120(6):1351-4.

13.

A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.

Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC.

Maturitas. 2006 Mar 20;53(4):413-23. Epub 2005 Sep 2.

PMID:
16140483
14.

Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.

Koskela-Niska V, Pukkala E, Lyytinen H, Ylikorkala O, Dyba T.

Int J Cancer. 2013 Oct 1;133(7):1680-8. doi: 10.1002/ijc.28167. Epub 2013 Apr 16.

15.

A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well.

Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI.

Int J Cancer. 2010 Jan 15;126(2):483-9. doi: 10.1002/ijc.24738.

16.

Occupation and risk of primary fallopian tube carcinoma in Nordic countries.

Riska A, Martinsen JI, Kjaerheim K, Lynge E, Sparen P, Tryggvadottir L, Weiderpass E, Pukkala E.

Int J Cancer. 2012 Jul 1;131(1):186-92. doi: 10.1002/ijc.26337. Epub 2011 Aug 30.

17.

Determinants of incidence of primary fallopian tube carcinoma (PFTC).

Riska A, Leminen A.

Methods Mol Biol. 2009;472:387-96. doi: 10.1007/978-1-60327-492-0_18. Review.

PMID:
19107444
18.

Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997.

Pukkala E, Tulenheimo-Silfvast A, Leminen A.

Cancer Causes Control. 2001 Feb;12(2):111-5.

PMID:
11246839
19.

Estrogen-progestin replacement therapy and endometrial cancer.

Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM.

J Natl Cancer Inst. 1997 Aug 6;89(15):1110-6.

20.

Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.

Du Y, Scheidt-Nave C, Schaffrath Rosario A, Ellert U, Dören M, Knopf H.

Climacteric. 2009 Aug;12(4):329-40. doi: 10.1080/13697130902745120.

PMID:
19437194
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk